🔍

Archit Organosys Ltd (524640)

📊 BSE: 524640 🏢 Commodity Chemicals 📢 Latest filing: 24 Sep 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Archit Organosys' revenue was ₹37.1 Cr (+11.7% year on year, +1.6% on the previous quarter), and net profit ₹1.4 Cr (-28.9% year on year); the operating margin was 9.1%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹37.1	+11.7%	+1.6%
Operating profit	₹3.4	-18.6%	-31.1%
Net profit	₹1.4	-28.9%	-28.2%
EPS (₹)	0.71	-28.3%	-27.6%
Operating margin	9.1%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Archit Organosys Withdraws 67.44% Acquisition of Archit Life Science and Preferential Issue

🔵 WATCH ⭐ 7/10

M&A 📅 24 Sep 2026, 08:03 PM

Archit Organosys has issued a corrigendum to its FY 2025-26 Annual Report, withdrawing three major agenda items from its upcoming AGM notice. Management dropped Item 8 (increase in authorized share capital), Item 9 (acquisition of up to 67.44% stake in Archit Life Science Limited as a material related-party transaction), and Item 10 (preferential issue of equity shares for consideration other than cash). Consequently, the related-party acquisition and dilution via preferential allotment will not be tabled for shareholder vote.

Withdrawn acquisition of up to 1,36,24,172 equity shares (67.44% stake) of M/s Archit Life Science Limited
Withdrawn preferential allotment of equity shares for consideration other than cash
Withdrawn proposal to increase Authorized Share Capital and alter Memorandum of Association
Separate resolution to increase Section 186 loan/guarantee limits from Rs 100.00 Cr to Rs 400.00 Cr remains on the agenda

💡 Track management commentary regarding why the acquisition was called off and monitor voting outcomes on the Section 186 limit hike to Rs 400 Cr.

Archit Organosys Withdraws Acquisition of 67.44% Stake in Archit Life Science from AGM Agenda

🔵 WATCH ⭐ 7/10

M&A 📅 24 Sep 2026, 07:08 PM

Archit Organosys Limited has issued a corrigendum to its 33rd Annual General Meeting notice scheduled for September 30, 2026, officially withdrawing three key resolutions. The withdrawn items include the acquisition of up to 1,36,24,172 equity shares (67.44% stake) in Archit Life Science Limited as a material related-party transaction, the associated preferential share issue (other than cash), and an increase in authorized share capital. However, resolutions regarding related-party transactions (advancing loans up to ₹75 crore and material supply up to ₹100 crore) and increasing Section 186 loan/investment limits to ₹400 crore remain on the agenda.

Item No. 9 withdrawn: Acquisition of up to 1,36,24,172 shares (67.44% equity) of Archit Life Science Limited cancelled from AGM agenda
Item No. 8 & 10 withdrawn: Increase in Authorized Share Capital and preferential share issuance (other than cash) dropped
Remaining Agenda Item 5: Proposed loan advances up to ₹75.00 crore and supply of goods up to ₹100.00 crore per year for FY27 and FY28 with Archit Life Science
Remaining Agenda Item 7: Proposed increase in limits under Section 186 from ₹100.00 crore to ₹400.00 crore
AGM to proceed via VC/OAVM on September 30, 2026, including dividend consideration of Re. 1/- (10%) per share

💡 Track the AGM voting results on September 30, 2026, and watch for management commentary or exchange disclosures regarding why the acquisition was cancelled and whether the related-party funding plans remain intact.

Archit Organosys Withdraws AGM Agendas to Acquire 67.44% Stake in Archit Life Science

🔵 WATCH ⭐ 7/10

M&A 📅 23 Sep 2026, 06:48 PM

Archit Organosys has approved the withdrawal of three key agenda items from its upcoming AGM on September 30, 2026. The withdrawn resolutions included the acquisition of up to 1,36,24,172 equity shares (a 67.44% stake) in Archit Life Science Limited as a Material Related Party Transaction, along with a related increase in authorized capital and a preferential issue of shares (other than cash). Management decided to withdraw the preferential issue in its current form to restructure the transaction. The company stated this withdrawal is not expected to adversely impact its financial position or operations.

Withdrew proposal to acquire 1,36,24,172 equity shares representing 67.44% of Archit Life Science Limited
Withdrew proposed preferential share allotment (other than cash) and increase in authorized share capital
Application for in-principle approval with BSE was in process prior to withdrawal
Withdrawal decided with a view to restructuring the proposed related-party transaction ahead of the September 30, 2026 AGM

💡 Track future board announcements regarding the revised deal terms and valuation structure for the Archit Life Science acquisition.

Archit Organosys Sets Sept 23, 2026 as Record Date for Final Dividend

🟡 NEUTRAL ⭐ 4/10

DIVIDEND 📅 03 Sep 2026, 08:23 PM

Archit Organosys Limited has announced September 23, 2026, as the record date to determine shareholder eligibility for its final dividend for FY 2025-26. The 33rd Annual General Meeting (AGM) is scheduled to be held on September 30, 2026. The register of members and share transfer books will remain closed from September 24 to September 29, 2026. Upon shareholder approval at the AGM, the dividend will be paid within 30 days.

Record date fixed as September 23, 2026 for final dividend entitlement
33rd Annual General Meeting to be held on September 30, 2026
Book closure set from September 24, 2026 to September 29, 2026
Dividend payout to be completed within 30 days of approval at the AGM

💡 Investors seeking dividend eligibility must hold shares before the ex-dividend date prior to September 23, 2026, and track AGM proceedings on September 30, 2026.

Archit Organosys to Consider Preferential Issue / Fundraise on Sep 3, 2026

🟡 NEUTRAL ⭐ 4/10

BOARD_MEETING 📅 27 Aug 2026, 07:40 PM

Archit Organosys Limited has scheduled a meeting of its Board of Directors for Thursday, September 3, 2026. The board will evaluate proposals for fund raising via issuance of equity shares, share warrants, or other equity-based instruments on a preferential / private placement basis. Specific details regarding the issue quantum, pricing, and dilution will be decided at the meeting and remain subject to shareholder and regulatory approvals.

Board meeting scheduled on September 3, 2026, to evaluate fundraising proposals
Fundraise modes under consideration include equity shares, share warrants, and preferential issue
Trading window closed for promoters, directors, and designated persons until 48 hours after board outcome

💡 Track the board meeting outcome on September 3, 2026, for the proposed quantum of capital, issue price, potential equity dilution, and deployment plans.

Archit Organosys Q1 Net Profit Drops 29% YoY to ₹1.45 Cr Despite 11.7% Revenue Growth

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 12 Aug 2026, 01:57 PM

Archit Organosys reported a mixed performance for Q1 FY27, with revenue from operations growing 11.7% YoY to ₹37.08 Cr. However, net profit declined significantly by 28.9% YoY to ₹1.45 Cr, down from ₹2.04 Cr in the same quarter last year. This profit compression was largely driven by a 41% surge in 'Other Expenses' and a 25% increase in power and fuel costs. Sequentially, while revenue remained relatively flat (up 1.6%), net profit fell 28.4% from ₹2.02 Cr in Q4 FY26.

Revenue from operations increased to ₹37.08 Cr in Q1 FY27 from ₹33.20 Cr in Q1 FY26.
Net profit for the quarter fell to ₹1.45 Cr compared to ₹2.04 Cr in the year-ago period.
Other expenses rose sharply by 41% YoY to ₹5.20 Cr from ₹3.69 Cr.
Power and fuel costs increased 25% YoY to ₹1.28 Cr.
Basic and Diluted EPS decreased to ₹0.71 from ₹0.99 in the corresponding previous quarter.

💡 Investors should monitor the company's ability to pass on rising operational costs (power and other expenses) to customers to protect margins in future quarters.

Archit Organosys Q1 PAT drops 29% YoY to ₹1.45 Cr despite 12% revenue growth

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 12 Aug 2026, 01:45 PM

Archit Organosys reported a mixed performance for Q1 FY27, with revenue from operations growing 11.7% YoY to ₹37.08 Cr. However, Net Profit declined significantly by 28.9% YoY to ₹1.45 Cr, down from ₹2.04 Cr in the same period last year. This profitability squeeze was driven by a 41% surge in 'Other Expenses' and higher power and fuel costs. The quarterly EPS consequently fell to ₹0.71 from ₹0.99 YoY.

Revenue from operations increased to ₹37.08 Cr from ₹33.20 Cr in the year-ago quarter.
Net Profit for the quarter stood at ₹1.45 Cr, a decline from ₹2.04 Cr in Q1 FY26.
Other expenses rose sharply to ₹5.20 Cr compared to ₹3.69 Cr in the previous year's corresponding quarter.
Power and fuel costs increased to ₹1.28 Cr from ₹1.03 Cr YoY.
Profit Before Tax (PBT) margin contracted to 5.4% from 8.9% in the year-ago period.

💡 Investors should monitor the trend in 'Other Expenses' and energy costs to determine if the current margin compression is structural or temporary. The company's ability to pass on cost increases in the commodity chemicals segment remains a key factor to watch in the next quarterly results.

Archit Organosys Board Meeting on August 12, 2026, to Approve Q1 FY27 Results

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 07 Aug 2026, 06:15 PM

Archit Organosys Ltd has scheduled a board meeting for August 12, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company, operating in the commodity chemicals sector, reported a TTM revenue of ₹113 Cr and a net profit of ₹3 Cr. Investors will be monitoring these results for signs of margin recovery, as operating margins compressed significantly from 15% in FY23 to 6% in FY24. The trading window for insiders has been closed since July 1, 2026.

Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results.
Trading window for promoters and directors closed from July 1, 2026.
Company reported TTM revenue of ₹113 Cr against a market cap of ₹125 Cr.
Operating profit margins (OPM) stood at 5.6% for the TTM period.
Net profit for the most recent reported quarter (Mar 2024) was ₹1.79 Cr.

💡 Monitor the official results release on August 12 to assess if the company can sustain the profitability seen in the March 2024 quarter (EPS ₹0.87) compared to the loss in December 2023.

View All 524640 Announcements on Live Market Tracking →